Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01249066

Enrollment

100

Registered

2010-11-29

Start date

2010-09-30

Completion date

Unknown

Last updated

2010-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Keywords

AMP-activated protein kinase, lung adenocarcinomas, Prognosis, Observation study

Brief summary

AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Lung cancer received operation lobectomy in CMUH

Exclusion criteria

* History of uremia, other malignant disease, and liver cirrhosis * History of pneumonia and pulmonary tuberculosis * History of long period of medications.

Countries

Taiwan

Outcome results